We report a case of tularemia presenting as a solitary pulmonary nodule following syngeneic PBSC transplant. Seven months after undergoing a syngeneic PBSC transplant for AML, our patient presented with fever without localizing signs. Chest X-ray revealed a solitary pulmonary nodule. Culture of a CT guided needle aspiration revealed Francisella tularensis. The patient was successfully treated with ciprofloxacin. His fever resolved and clearance of the nodule was documented on a CT scan 2 months after diagnosis and initiation of treatment. To our knowledge, this is the only reported case of tularemia occurring in the post-transplant setting. The possible relationship between transplantinduced immune dysfunction and the occurrence of this rare infection is discussed. Keywords: tularemia; PBSC transplant Case report DM was diagnosed with AML (FAB M4) in June of 1996 at the age of 61. He underwent induction chemotherapy with idarubicin and Ara-C, followed by consolidation with high-dose Ara-C. This resulted in a complete remission. He subsequently underwent syngeneic peripheral blood stem cell (PBSC) transplantation in first remission using a conditioning regimen consisting of busulfan 4 mg/kg p.o. in divided doses daily for 4 days (total dose 16 mg/kg) and cyclophosphamide 60 mg/kg once daily i.v. for 2 days (total dose 120 mg/kg). No GVHD prophylaxis was administered.
Case report
DM was diagnosed with AML (FAB M4) in June of 1996 at the age of 61. He underwent induction chemotherapy with idarubicin and Ara-C, followed by consolidation with high-dose Ara-C. This resulted in a complete remission. He subsequently underwent syngeneic peripheral blood stem cell (PBSC) transplantation in first remission using a conditioning regimen consisting of busulfan 4 mg/kg p.o. in divided doses daily for 4 days (total dose 16 mg/kg) and cyclophosphamide 60 mg/kg once daily i.v. for 2 days (total dose 120 mg/kg). No GVHD prophylaxis was administered.
Approximately 7 months after transplant, the patient presented to an outside hospital with a 4-day history of fever, chills and fatigue. He had no localizing symptoms, and denied cough, shortness of breath and chest pain. He was empirically treated with ceftriaxone for a temperature of 39.2°C. Despite this antibiotic cover, his fever persisted for 4 days. Admission chest X-ray revealed a possible right lower lobe nodule (Figure 1 ). Subsequent CT scan of the chest confirmed a 3.3 ϫ 3.0 cm nodule in the right lower lobe. There were no other significant findings and his blood and urine cultures remained negative.
He was transferred to Washington University Medical Center and his antibiotic cover was changed to imipenem. A CT guided needle aspiration of the nodule was performed. All stains for microorganisms, including AFB, were negative. The patient became afebrile and clinically improved after 3 days of therapy with imipenem. On the following day, he underwent bronchoalveolar lavage with transbronchial biopsies. Again, all stains were negative. Two days later, cultures from the CT guided needle aspiration grew gram-negative bacilli. The following day the organism was identified as Francisella tularensis.
The patient was known to live on a farm, but had not actively participated in farming for several years. He had been a hunter in the past, but had not been hunting in sev- eral years. The patient did not recall a tick bite or direct tick exposure.
When the culture results became available it was decided to use ciprofloxacin as primary therapy, as the patient had a history of ototoxicity with gentamicin. The imipenem was discontinued after 1 week of therapy, and he was discharged home to complete a 28-day course of ciprofloxacin, 750 mg twice a day. A repeat CT scan 3 weeks after admission revealed improvement in the mass with decreased size and areas of focal clearing within the mass. A CT scan performed 7 weeks after admission, and 6 weeks after initiating oral ciprofloxacin, revealed almost complete resolution of the solitary pulmonary nodule. The patient remains clinically well and off antibiotics 16 months following his diagnosis of pulmonary tularemia, and 23 months after syngeneic PBSC transplant.
Discussion
Francisella tularensis is a gram-negative intracellular, coccobacilli first identified as the cause of a 'plague-like' illness in rodents by McCoy in 1911. 1 Since then the epidemiology of the human disease has been more fully defined. Tularemia is a relatively rare cause of infection in humans in the US, with fewer than 200 cases reported annually. Half of these cases occur in Arkansas, Oklahoma and Missouri. 2 Infections have most commonly been associated with the handling of the raw flesh of infected animals, direct inoculation by infected arthropods, or by inhalation of aerosolized particles from contaminated hay. Men account for approximately 75% of cases, presumably due to higher risk for exposure from hunting, farming, or other outdoor activities. 3 Tularemia infections are generally divided into distinct clinical syndromes. Ulceroglandular disease, which is characterized by an ulcer with localized enlarged lymphadenopathy, is the most common presentation. Typhoidal disease, which is characterized by fever and signs and symptoms of a systemic infection, is the form more commonly associated with pulmonary involvement. Approximately 25% of patients with typhoidal disease have been found to exhibit pulmonary involvement. Patients with pulmonary involvement have been found to be older, to be less likely to have a known vector exposure, to require a longer hospitalization, to present with fever, to be more likely to have positive cultures, and to be more likely to have a fatal outcome. 4 Pulmonary tularemia is generally described as an alveolar infiltrate or pleural effusion, but pulmonary nodules have also infrequently been described. 5 The relationship between the immunosuppressive effects of this patient's syngeneic transplant and his infection are not clear. It is possible that they are unrelated. The possibility also exists that transplant-related lymphocyte dysfunction may have contributed to the occurrence of tularemia in this patient.
Patients receiving BM or PBSC transplants experience leukocyte recovery 10 to 20 days following transplant. However, they also manifest lymphocyte dysfunction for several months following transplant, whether they undergo autologous, syngeneic or allogeneic transplant. Regeneration of antigen-specific T lymphocytes is seen only after reacquisition of a population of naive T cells. 10 In addition, T cell proliferation to PHA, allogeneic MHC, and anti-CD3 remains impaired up to 12 months following allogeneic transplant.
11
Our patient was 7 months post-syngeneic PBSC transplant when he was diagnosed with tularemia. We did not perform T cell subset analysis or T cell functional assays in this patient. It is, therefore, speculative that impaired T cell function contributed to the acquisition of this infection. From studies of the host response to tularemia, it does seem that intact lymphocyte function plays a critical role in the immune response to this organism. [12] [13] [14] It has previously been shown that mononuclear leukocytes confer resistance to F. tularensis. 15, 16 It is also known that T cells can confer adoptive resistance to tularemia. 17 This case describes the occurrence of pulmonary tularemia, a rare infection, in the post-transplant setting. Whether or not the immunodeficiency associated with transplantation contributed to this infection cannot be conclusively determined. This patient's response to ciprofloxacin adds to the growing experience with fluoroquinolones in the treatment of tularemia.
